Recently, The Bisthianostat, a class 1.1 anti-cancer Investigational New Drug(IND), independently developed by Shanghai Institute of Materia Medica (SIMM), CAS was approved into clincal trial by the State Food and Drug Administration of China (CFDA). 

Bisthianostat is a new type of bisthiazol-based pan- HDAC (histone deacetylase) inhibitor, which was developed by SIMM researchers and preclinical developed in collaboration with researchers from pharmaceutical companies.